Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 17/20 | 0.74 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.59 |
| ▸ | IGF1R | P08069 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13801983 | 0.91 | PTK2 (0.70) | PTK2LRRK2IGF1R | |
| SCHEMBL16130900 | 0.90 | PTK2 (0.91) | PTK2 | |
| SCHEMBL18949857 | 0.90 | PTK2 (0.91) | PTK2 | |
| SCHEMBL14454135 | 0.85 | LRRK2 (0.58) | PTK2LRRK2IGF1R | |
| SCHEMBL12135104 | 0.85 | PTK2 (1.00) | PTK2 | |
| SCHEMBL12135185 | 0.83 | PTK2 (1.00) | PTK2 | |
| SCHEMBL12135107 | 0.82 | PTK2 (1.00) | PTK2 | |
| SCHEMBL12562699 | 0.81 | LRRK2 (0.56) | PTK2LRRK2IGF1R | |
| SCHEMBL12135103 | 0.79 | PTK2 (1.00) | PTK2 | |
| SCHEMBL29381547 | 0.79 | PTK2 (1.00) | PTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110086842-A1 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-04-14 | — | — | US | disclosed |
| US-20110086842-A1 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-04-14 | — | — | US | disclosed |
| US-20090149438-A1 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-11 | — | — | US | disclosed |
| US-20090149438-A1 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-11 | — | — | US | disclosed |
| US-7521457-B2 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-21 | — | — | US | disclosed |
| US-7521457-B2 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086842-A1 | Pyrimidines as PLK inhibitors | PLK2, PLK3, TYMP | PTK2 833/4885LRRK2 1725/4885IGF1R 493/4885 |
| US-20090149438-A1 | Pyrimidines as PLK inhibitors | PLK2, PLK3, TYMP | PTK2 833/4885LRRK2 1725/4885IGF1R 493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.